| Prediction of Lymph Node Invasion for Prostate Adenocarcinoma (NCT04909957) | University Hospital, Brest | 2021-01-01 |
| Prospective Prostate Cancer and Patient-reported Outcomes Registry (NCT04694924) | Universitaire Ziekenhuizen KU Leuven | 2020-10-01 |
| Evaluation of the Efficacy and the Safety of a Stereotaxic Prostatic Radiotherapy Delivered With Linac MRI, in Patients With Prostate Adenocarcinoma (NCT04909294) | Centre Georges Francois Leclerc | 2020-10-01 |
| Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma (NCT04586543) | László Mangel | 2020-05-18 |
| First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients. (NCT04097002) | Orca Therapeutics B.V. | 2019-11-12 |
| Muscadine Plus (MPX) In Men With Prostate Cancer (NCT03535675) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2018-10-30 |
| Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer (NCT03686683) | Dendreon | 2018-10-18 |
| Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8) (NCT03689699) | Mark Stein | 2018-10-11 |
| Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer (NCT03624660) | University of Florida | 2018-09-24 |
| Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer (NCT03511196) | H. Lee Moffitt Cancer Center and Research Institute | 2018-09-17 |
| BrUOG 337: Olaparib Prior to Radical Prostatectomy For Advanced Prostate Cancer Defects in DNA Repair Genes (NCT03432897) | Brown University | 2018-05-25 |
| Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer (NCT03077659) | NanOlogy, LLC | 2017-09-06 |
| Utilising CTC Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer (NCT03327662) | Institute of Cancer Research, United Kingdom | 2017-01-11 |
| Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer (NCT02278185) | University of Colorado, Denver | 2015-11-11 |
| Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy (NCT02523924) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2015-06-02 |
| Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy (NCT02203695) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2015-03-28 |
| Intra-operative Optical Imaging With MDX1201-A488 in Patients With Prostate Cancer (NCT02048150) | City of Hope Medical Center | 2015-03-13 |
| A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC (NCT02525068) | Institute of Cancer Research, United Kingdom | 2014-12-01 |
| Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer (NCT02176902) | Jonsson Comprehensive Cancer Center | 2014-11-01 |
| Pilot Study of DRibble Vaccine for Prostate Cancer Patients (NCT02234921) | UbiVac | 2014-10-24 |
| Intraoperative Dosimetry for Prostate Brachytherapy Using Fluoroscopy and Ultrasound (NCT02225925) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2014-10-01 |
| Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer (NCT02217709) | University of Southern California | 2014-09-08 |
| Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer (NCT02184533) | Stanford University | 2014-07-01 |
| LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer (NCT02058706) | Barbara Ann Karmanos Cancer Institute | 2014-05-01 |
| Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer (NCT02296229) | Jonsson Comprehensive Cancer Center | 2014-01-27 |
| Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer (NCT01949337) | Alliance for Clinical Trials in Oncology | 2014-01-22 |
| Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery (NCT01912820) | Jonsson Comprehensive Cancer Center | 2014-01-01 |
| Enzalutamide in Patients With High-risk Prostate Cancer (NCT01927627) | Case Comprehensive Cancer Center | 2013-11-11 |
| Docetaxel and Lycopene in Metastatic Prostate Cancer (NCT01949519) | Medical University of South Carolina | 2013-11-01 |
| Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT01866423) | University of Southern California | 2013-10-25 |
| Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer (NCT01848067) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2013-08-14 |
| A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection (NCT01832259) | University of Utah | 2013-08-01 |
| Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT01913015) | OHSU Knight Cancer Institute | 2013-07-01 |
| Cabozantinib in Men With Castration-Resistant Prostate Cancer (NCT01703065) | University of Washington | 2013-06-18 |
| Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer (NCT01807065) | City of Hope Medical Center | 2013-06-07 |
| Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate (NCT02064036) | University of California, Davis | 2013-06-06 |
| Radiation and Androgen Ablation for Prostate Cancer (NCT01517451) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2013-05-22 |
| Hypofractionated Image-Guided Radiotherapy (IGRT) With Organ Motion Mitigation and Urethral Sparing for Prostate Cancer (NCT02761889) | Fundacao Champalimaud | 2013-05-01 |
| Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer (NCT01812668) | Barbara Ann Karmanos Cancer Institute | 2013-03-01 |
| Active Surveillance of 2 Groups of Patients With Localized Prostate Cancer (NCT01795365) | Centre Hospitalier Universitaire Vaudois | 2012-12-01 |
| High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer (NCT01655836) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2012-10-04 |
| High-Dose Stereotactic Radiation for Prostate Cancer (NCT01664130) | Case Comprehensive Cancer Center | 2012-07-01 |
| TOPARP: A Phase II Trial of Olaparib in Patients With Advanced Castration Resistant Prostate Cancer (NCT01682772) | Institute of Cancer Research, United Kingdom | 2012-07-01 |
| Internal Radiation Therapy in Treating Patients With Low-Risk Prostate Cancer (NCT01859689) | Jonsson Comprehensive Cancer Center | 2012-03-01 |
| Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT01498978) | OHSU Knight Cancer Institute | 2012-02-06 |
| Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer (NCT01533246) | National Cancer Institute (NCI) | 2012-02-01 |
| Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer (NCT01174199) | Roswell Park Cancer Institute | 2012-02-01 |
| EPISPOT Detection of Circulating Prostate Cells Among Adenocarcinoma Patients (NCT01402154) | Centre Hospitalier Universitaire de Nīmes | 2012-01-03 |
| Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery (NCT01433913) | National Cancer Institute (NCI) | 2011-11-01 |
| Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT01468532) | Barbara Ann Karmanos Cancer Institute | 2011-10-01 |
| Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer (NCT01054079) | Wake Forest University Health Sciences | 2011-09-01 |
| The Prostate Immobilization Device Study (NCT01408706) | James Taylor | 2011-08-01 |
| STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling (NCT01368003) | Toni Choueiri, MD | 2011-04-01 |
| Genistein in Treating Patients With Prostate Cancer (NCT01126879) | Northwestern University | 2011-02-03 |
| Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients (NCT01882985) | University of California, Irvine | 2010-12-01 |
| Sulforaphane in Treating Patients With Recurrent Prostate Cancer (NCT01228084) | OHSU Knight Cancer Institute | 2010-11-01 |
| A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen (NCT01094288) | Millennium Pharmaceuticals, Inc. | 2010-08-17 |
| Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer (NCT01200810) | National Cancer Institute (NCI) | 2010-08-01 |
| Intensity-Modulated External Beam Radiation Therapy in Treating Patients With Prostate Cancer (NCT01117935) | Virginia Commonwealth University | 2010-05-30 |
| Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer (NCT01093183) | University of Nebraska | 2010-03-04 |
| Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer (NCT01023061) | University of Washington | 2010-03-01 |
| Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer (NCT01050842) | Mayo Clinic | 2010-02-01 |
| Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma Prostate (NCT01255891) | Dr. Tamim Niazi | 2010-01-01 |
| Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients (NCT00879619) | John P. Fruehauf | 2009-07-01 |
| R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer (NCT00666666) | National Cancer Institute (NCI) | 2009-07-01 |
| MRI-Guided Radiation Therapy in Treating Patients Who Have Undergone Surgery to Remove the Prostate (NCT01028885) | Abramson Cancer Center at Penn Medicine | 2009-06-01 |
| Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate (NCT00598858) | John P. Fruehauf | 2009-01-01 |
| Diffusion-Weighted MRI in Staging Patients With Localized Prostate Cancer (NCT02237612) | University of Southern California | 2009-01-01 |
| Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer (NCT00450749) | National Cancer Institute (NCI) | 2008-02-01 |
| Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy (NCT00527124) | National Cancer Institute (NCI) | 2007-11-01 |
| Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer (NCT00512668) | National Cancer Institute (NCI) | 2007-09-01 |
| Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer (NCT00520481) | Eli Lilly and Company | 2007-08-01 |
| Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer (NCT00570700) | University of California, Irvine | 2007-07-01 |
| Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy (NCT01656304) | Barbara Ann Karmanos Cancer Institute | 2007-05-01 |
| A Study of BAY 43-9006 in Combination With Bicalutamide in Patients With Chemo-Naïve Hormone Refractory Prostate Cancer (NCT00430235) | British Columbia Cancer Agency | 2007-03-01 |
| Defined Green Tea Catechins in Treating Patients With Prostate Cancer Undergoing Surgery to Remove the Prostate (NCT00459407) | National Cancer Institute (NCI) | 2007-03-01 |
| Single Photon Emission Computed Tomography (SPECT) Lymph Node Mapping (NCT00608920) | Washington University School of Medicine | 2007-03-01 |
| Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer (NCT00450229) | National Cancer Institute (NCI) | 2007-02-01 |
| Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery (NCT00438464) | National Cancer Institute (NCI) | 2007-02-01 |
| Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer (NCT00466752) | University of Washington | 2006-12-01 |
| Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy (NCT00337077) | National Cancer Institute (NCI) | 2006-11-01 |
| Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy (NCT00321646) | Mary-Ellen Taplin, MD | 2006-06-01 |
| Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy (NCT00331344) | National Cancer Institute (NCI) | 2006-04-01 |
| Intensity Modulated Radiation Therapy (IMRT) Pelvic Nodes Prostate (NCT00915122) | University Health Network, Toronto | 2005-11-01 |
| Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy (NCT00110214) | National Cancer Institute (NCI) | 2005-04-01 |
| SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel (NCT00096499) | National Cancer Institute (NCI) | 2005-04-01 |
| Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer (NCT00109811) | National Cancer Institute (NCI) | 2005-03-01 |
| 17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy (NCT00118092) | National Cancer Institute (NCI) | 2005-01-01 |
| Ixabepilone in Treating Patients With Metastatic Prostate Cancer (NCT00087139) | National Cancer Institute (NCI) | 2004-09-01 |
| Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer (NCT00080899) | National Cancer Institute (NCI) | 2004-06-01 |
| Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment (NCT00165399) | Dana-Farber Cancer Institute | 2004-03-01 |
| A Prospective Randomized Phase III Study Comparing Hormonal Therapy +/-Docetaxel (NCT00764166) | Assistance Publique - Hôpitaux de Paris | 2003-06-01 |
| Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer (NCT00058084) | National Cancer Institute (NCI) | 2003-03-01 |
| Perifosine in Treating Patients With Recurrent Prostate Cancer (NCT00058214) | National Cancer Institute (NCI) | 2003-03-01 |
| High Dose-Rate Brachytherapy and/or Intensity Modulated External Beam Radiation Therapy for Prostate Cancer (NCT00243321) | Virginia Commonwealth University | 2003-02-01 |
| BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy (NCT00040755) | National Cancer Institute (NCI) | 2002-05-01 |
| Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer (NCT00039104) | National Cancer Institute (NCI) | 2002-04-01 |
| Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone (NCT00181558) | Massachusetts General Hospital | 2001-12-01 |
| Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer (NCT00016107) | National Cancer Institute (NCI) | 2001-06-01 |
| Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer (NCT00182052) | Massachusetts General Hospital | 2000-09-01 |